RU2614252C2 - Антитела, которые связывают интегрин альфа-v бета-8 - Google Patents

Антитела, которые связывают интегрин альфа-v бета-8 Download PDF

Info

Publication number
RU2614252C2
RU2614252C2 RU2014109928A RU2014109928A RU2614252C2 RU 2614252 C2 RU2614252 C2 RU 2614252C2 RU 2014109928 A RU2014109928 A RU 2014109928A RU 2014109928 A RU2014109928 A RU 2014109928A RU 2614252 C2 RU2614252 C2 RU 2614252C2
Authority
RU
Russia
Prior art keywords
seq
antibody
αvβ8
disease
antibodies
Prior art date
Application number
RU2014109928A
Other languages
English (en)
Russian (ru)
Other versions
RU2014109928A (ru
Inventor
Стивен НИШИМУРА
Цзяньлон ЛОУ
Джоди Линн БАРОН
Джеймс МАРКС
Original Assignee
Те Риджентс Оф Те Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Те Риджентс Оф Те Юниверсити Оф Калифорния filed Critical Те Риджентс Оф Те Юниверсити Оф Калифорния
Publication of RU2014109928A publication Critical patent/RU2014109928A/ru
Application granted granted Critical
Publication of RU2614252C2 publication Critical patent/RU2614252C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2014109928A 2011-08-17 2012-08-17 Антитела, которые связывают интегрин альфа-v бета-8 RU2614252C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161524708P 2011-08-17 2011-08-17
US61/524,708 2011-08-17
US201261646111P 2012-05-11 2012-05-11
US61/646,111 2012-05-11
PCT/US2012/051373 WO2013026004A2 (en) 2011-08-17 2012-08-17 Antibodies that bind integrin alpha-v beta-8

Publications (2)

Publication Number Publication Date
RU2014109928A RU2014109928A (ru) 2015-09-27
RU2614252C2 true RU2614252C2 (ru) 2017-03-24

Family

ID=47715714

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014109928A RU2614252C2 (ru) 2011-08-17 2012-08-17 Антитела, которые связывают интегрин альфа-v бета-8

Country Status (13)

Country Link
US (1) US9492569B2 (enExample)
EP (1) EP2744823B1 (enExample)
JP (1) JP6093360B2 (enExample)
KR (1) KR102010098B1 (enExample)
CN (1) CN103857696B (enExample)
AU (1) AU2012296362B2 (enExample)
BR (1) BR112014003501B1 (enExample)
CA (1) CA2846240C (enExample)
ES (1) ES2643397T3 (enExample)
MX (1) MX350335B (enExample)
RU (1) RU2614252C2 (enExample)
SG (1) SG2014014237A (enExample)
WO (1) WO2013026004A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12371499B2 (en) 2018-09-07 2025-07-29 The Regents Of The University Of California Method of treating cancer using anti-AV8 antibodies

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219560A3 (en) * 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody
SG11201509982UA (enExample) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
PT3157561T (pt) * 2014-06-17 2020-03-25 Univ California Anticorpos contra alfa-v beta-8 melhorados
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
US10954304B2 (en) 2016-09-29 2021-03-23 The Regents Of The University Of California Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
JP7370252B2 (ja) * 2017-05-30 2023-10-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 神経炎症性疾患の治療
WO2020102422A1 (en) * 2018-11-14 2020-05-22 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
TWI854088B (zh) * 2020-01-27 2024-09-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
CN120225559A (zh) * 2022-09-12 2025-06-27 国家健康与医学研究院 新型抗itgb8抗体及其用途
WO2024206788A1 (en) * 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024258908A1 (en) * 2023-06-12 2024-12-19 University Of Washington De novo designed alpha (v) beta (8) integrin selective minibinder
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635601A (en) * 1991-03-14 1997-06-03 Genentech, Inc. Beta-8 integrin subunit antibodies
RU2205223C2 (ru) * 1994-12-20 2003-05-27 Мерк Патент Гмбх МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ αV-ИНТЕГРИНОВ (ВАРИАНТЫ), ЕГО ПОЛУЧЕНИЕ (ВАРИАНТЫ) И ИСПОЛЬЗОВАНИЕ, ГИБРИДОМА, ПОЛИПЕПТИД, ДНК

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US7803553B2 (en) * 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
EP3476861A1 (en) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-specific monoclonal antibody and uses thereof
WO2010022737A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Anti-cd5 antibodies
SG178348A1 (en) * 2009-08-19 2012-03-29 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
EP4219560A3 (en) * 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635601A (en) * 1991-03-14 1997-06-03 Genentech, Inc. Beta-8 integrin subunit antibodies
RU2205223C2 (ru) * 1994-12-20 2003-05-27 Мерк Патент Гмбх МОНОКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ αV-ИНТЕГРИНОВ (ВАРИАНТЫ), ЕГО ПОЛУЧЕНИЕ (ВАРИАНТЫ) И ИСПОЛЬЗОВАНИЕ, ГИБРИДОМА, ПОЛИПЕПТИД, ДНК

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MU D. et al., "The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1", J Cell Biol. 2002 Apr 29;157(3):493-507. ARAVA J. et al., "Integrin-mediated transforming growth factor-beta activation regulates homeostasis of the pulmonary epithelial-mesenchymal trophic unit", Am J Pathol. 2006 Aug;169(2):405-15. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12371499B2 (en) 2018-09-07 2025-07-29 The Regents Of The University Of California Method of treating cancer using anti-AV8 antibodies

Also Published As

Publication number Publication date
WO2013026004A3 (en) 2013-06-13
JP2015501285A (ja) 2015-01-15
JP6093360B2 (ja) 2017-03-08
ES2643397T3 (es) 2017-11-22
AU2012296362B2 (en) 2017-06-29
EP2744823B1 (en) 2017-08-02
US20140271478A1 (en) 2014-09-18
CN103857696B (zh) 2017-07-04
KR102010098B1 (ko) 2019-08-13
CN103857696A (zh) 2014-06-11
MX2014001850A (es) 2014-12-08
BR112014003501B1 (pt) 2022-02-08
WO2013026004A2 (en) 2013-02-21
AU2012296362A1 (en) 2014-03-13
MX350335B (es) 2017-09-04
EP2744823A2 (en) 2014-06-25
EP2744823A4 (en) 2015-08-12
CA2846240A1 (en) 2013-02-21
US9492569B2 (en) 2016-11-15
CA2846240C (en) 2021-01-12
SG2014014237A (en) 2014-07-30
BR112014003501A2 (pt) 2017-03-01
KR20140054238A (ko) 2014-05-08
RU2014109928A (ru) 2015-09-27

Similar Documents

Publication Publication Date Title
RU2614252C2 (ru) Антитела, которые связывают интегрин альфа-v бета-8
US12110334B2 (en) Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
ES2469369T3 (es) Anticuerpos anti-CXCR4 humanizados para el tratamiento del cáncer
KR101857310B1 (ko) 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
JP6037149B2 (ja) 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体
KR20150023355A (ko) Ｃｌｌ-1 에 특이적인 항체
MX2011004684A (es) Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
CN102847148A (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
CN115920078A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
CN110300761B (zh) 抗pcna单克隆抗体及其用途
JP2019513815A (ja) Ｃ１不活性化物質、ｃ反応性蛋白質及び／又は補体成分ｃ４に結合する抗体を用いて癌を診断及び治療する方法
CA3157048A1 (en) Humanized anti-ca ix antibodies and methods of their use
HK1196971B (en) Antibodies that bind integrin alpha-v beta-8
HK1196971A (en) Antibodies that bind integrin alpha-v beta-8
Fan Preclinical studies of CD103 molecular imaging to guide cancer immunotherapy
HK40008779A (en) NEUTRALIZING ANTIBODIES TO THE αVβ8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
HK40008779B (zh) 用於免疫疗法的αvβ8整联蛋白复合物的中和抗体
HK40008251A (en) Anti-pcna monoclonal antibodies and use thereof